220 related articles for article (PubMed ID: 23023518)
1. Virtual screening and synthesis of new chemical scaffolds as VEGFR-2 kinase inhibitors.
Elsayed MS; El-Araby ME; Serya RT; Abouzid KA
Arzneimittelforschung; 2012 Dec; 62(12):554-60. PubMed ID: 23023518
[TBL] [Abstract][Full Text] [Related]
2. Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors.
Lee K; Jeong KW; Lee Y; Song JY; Kim MS; Lee GS; Kim Y
Eur J Med Chem; 2010 Nov; 45(11):5420-7. PubMed ID: 20869793
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological testing of novel pyridoisothiazolones as histone acetyltransferase inhibitors.
Furdas SD; Shekfeh S; Bissinger EM; Wagner JM; Schlimme S; Valkov V; Hendzel M; Jung M; Sippl W
Bioorg Med Chem; 2011 Jun; 19(12):3678-89. PubMed ID: 21353783
[TBL] [Abstract][Full Text] [Related]
4. Computational approach to the identification of novel Aurora-A inhibitors.
Morshed MN; Cho YS; Seo SH; Han KC; Yang EG; Pae AN
Bioorg Med Chem; 2011 Jan; 19(2):907-16. PubMed ID: 21194953
[TBL] [Abstract][Full Text] [Related]
5. Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors.
Li Y; Tan C; Gao C; Zhang C; Luan X; Chen X; Liu H; Chen Y; Jiang Y
Bioorg Med Chem; 2011 Aug; 19(15):4529-35. PubMed ID: 21724404
[TBL] [Abstract][Full Text] [Related]
6. Improving VEGFR-2 docking-based screening by pharmacophore postfiltering and similarity search postprocessing.
Planesas JM; Claramunt RM; Teixidó J; Borrell JI; Pérez-Nueno VI
J Chem Inf Model; 2011 Apr; 51(4):777-87. PubMed ID: 21417262
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel EGFR tyrosine kinase inhibitors by structure-based virtual screening.
Li S; Sun X; Zhao H; Tang Y; Lan M
Bioorg Med Chem Lett; 2012 Jun; 22(12):4004-9. PubMed ID: 22595177
[TBL] [Abstract][Full Text] [Related]
8. Structure-guided identification of novel VEGFR-2 kinase inhibitors via solution phase parallel synthesis.
Tripathy R; Reiboldt A; Messina PA; Iqbal M; Singh J; Bacon ER; Angeles TS; Yang SX; Albom MS; Robinson C; Chang H; Ruggeri BA; Mallamo JP
Bioorg Med Chem Lett; 2006 Apr; 16(8):2158-62. PubMed ID: 16460933
[TBL] [Abstract][Full Text] [Related]
9. A combination of 2D similarity search, pharmacophore, and molecular docking techniques for the identification of vascular endothelial growth factor receptor-2 inhibitors.
Ai G; Tian C; Deng D; Fida G; Chen H; Ma Y; Ding L; Gu Y
Anticancer Drugs; 2015 Apr; 26(4):399-409. PubMed ID: 25569705
[TBL] [Abstract][Full Text] [Related]
10. Pharmacophore modeling and in silico screening for new KDR kinase inhibitors.
Yu H; Wang Z; Zhang L; Zhang J; Huang Q
Bioorg Med Chem Lett; 2007 Apr; 17(8):2126-33. PubMed ID: 17306530
[TBL] [Abstract][Full Text] [Related]
11. Multiple pharmacophore models combined with molecular docking: a reliable way for efficiently identifying novel PDE4 inhibitors with high structural diversity.
Chen Z; Tian G; Wang Z; Jiang H; Shen J; Zhu W
J Chem Inf Model; 2010 Apr; 50(4):615-25. PubMed ID: 20353193
[TBL] [Abstract][Full Text] [Related]
12. Discovery of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors.
Shi L; Wu TT; Wang Z; Xue JY; Xu YG
Eur J Med Chem; 2014 Sep; 84():698-707. PubMed ID: 25064347
[TBL] [Abstract][Full Text] [Related]
13. Exploration of acridine scaffold as a potentially interesting scaffold for discovering novel multi-target VEGFR-2 and Src kinase inhibitors.
Luan X; Gao C; Zhang N; Chen Y; Sun Q; Tan C; Liu H; Jin Y; Jiang Y
Bioorg Med Chem; 2011 Jun; 19(11):3312-9. PubMed ID: 21576023
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel anaplastic lymphoma kinase (ALK) inhibitors using a common feature pharmacophore model derived from known ligands crystallized with ALK.
Xie HZ; Lan H; Pan YL; Zou J; Wang ZR; Li LL; Huang Q; Zhang H; Yang SY
Chem Biol Drug Des; 2013 Feb; 81(2):175-84. PubMed ID: 23107363
[TBL] [Abstract][Full Text] [Related]
15. Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer.
Garofalo A; Goossens L; Lemoine A; Farce A; Arlot Y; Depreux P
J Enzyme Inhib Med Chem; 2010 Apr; 25(2):158-71. PubMed ID: 20222760
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel Bruton's tyrosine kinase inhibitors using a hybrid protocol of virtual screening approaches based on SVM model, pharmacophore and molecular docking.
Wan HL; Wang ZR; Li LL; Cheng C; Ji P; Liu JJ; Zhang H; Zou J; Yang SY
Chem Biol Drug Des; 2012 Sep; 80(3):366-73. PubMed ID: 22594639
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and structure-activity relationships of (aryloxy)quinazoline ureas as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors.
Garofalo A; Farce A; Ravez S; Lemoine A; Six P; Chavatte P; Goossens L; Depreux P
J Med Chem; 2012 Feb; 55(3):1189-204. PubMed ID: 22229669
[TBL] [Abstract][Full Text] [Related]
18. Discovery and molecular docking of quinolyl-thienyl chalcones as anti-angiogenic agents targeting VEGFR-2 tyrosine kinase.
Rizvi SU; Siddiqui HL; Nisar M; Khan N; Khan I
Bioorg Med Chem Lett; 2012 Jan; 22(2):942-4. PubMed ID: 22200597
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel vascular endothelial growth factor receptor 2 inhibitors: a virtual screening approach.
Zhang L; Wang X; Feng J; Jia Y; Xu F; Xu W
Chem Biol Drug Des; 2012 Dec; 80(6):893-901. PubMed ID: 22913881
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel indolyl-1,2,4-triazole hybrids as potent vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors with potential anti-renal cancer activity.
Al-Hussain SA; Farghaly TA; Zaki MEA; Abdulwahab HG; Al-Qurashi NT; Muhammad ZA
Bioorg Chem; 2020 Dec; 105():104330. PubMed ID: 33038552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
